Interleukin-8 expression associated with canine mammary tumors

Genetics and Molecular Research

Volumn 10, Issue 3, 2011, Pages 1522-1532

  Zuccari, D A P C ^a,b   Castro, R ^a   Gelaleti, G B ^b   Mancini, U M ^c  

^a FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Immunohistochemistry; Interleukin 8; Mammary cancer; Prognosis; Real time PCR

Indexed keywords

INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY;

ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CANCER CELL; CONTROLLED STUDY; DOG; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; DOG DISEASES; DOGS; FEMALE; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; MAMMARY NEOPLASMS, ANIMAL; REAL-TIME POLYMERASE CHAIN REACTION;

CANIS FAMILIARIS;

EID: 80955167033     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/vol10-3gmr1145     Document Type: Article

References (39)

1. Allred DC, Harvey JM, Berardo M and Clark GM (1998). Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11: 155-168.
2. Benoy IH, Salgado R, Van Dam P, Geboers K, et al. (2004). Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin. Cancer Res. 10: 7157-7162.
3. Bobrovnikova-Marjon EV, Marjon PL, Barbash O, Vander Jagt DL, et al. (2004). Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-kappaB and activating protein-1. Cancer Res. 64: 4858-4869.
4. Brodey RS, Goldschmidt MH and Roszel JR (1983). Canine mammary gland neoplasms. J. Am. Anim. Hosp. Assoc. 19: 61-69.
5. Cordeiro JA (1987). Análises de Dependência. Relatório Técnico No. 48/87. Instituto de Matemática e Estatística UNICAMP, Campinas.
6. De Larco JE, Wuertz BR, Rosner KA, Erickson SA, et al. (2001). A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am. J. Pathol. 158: 639-646.
7. De Larco JE, Wuertz BR, Yee D, Rickert BL, et al. (2003). Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 100: 13988-13993.
8. Derin D, Soydinc HO, Guney N, Tas F, et al. (2007). Serum IL-8 and IL-12 levels in breast cancer. Med. Oncol. 24: 163-168.
9. Elston CW and Ellis IO (Editors) (1998). Assessment of Histological Grade. In: The Breast. Vol. 13. Churchill Livingstone, Edinburgh, New York, 356-384.
10. Ferreira E, Bertagnolli AC, Cavalcanti MF, Schmitt FC, et al. (2009). The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours. Vet. Comp. Oncol. 7: 230-235.
11. Freund A, Jolivel V, Durand S, Kersual N, et al. (2004). Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23: 6105-6114.
12. Karayannopoulou M, Kaldrymidou E, Constantinidis TC and Dessiris A (2005). Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J. Comp. Pathol. 133: 246-252.
13. Knupfer H, Schmidt R, Stanitz D, Brauckhoff M, et al. (2004). CYP2C and IL-6 expression in breast cancer. Breast 13: 28-34.
14. Lee LF, Hellendall RP, Wang Y, Haskill JS, et al. (2000). IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J. Immunol. 164: 2769-2775.
15. Li Q, Bostick-Bruton F and Reed E (1998). Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line. Anticancer Res. 18: 2283-2287.
16. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt Method. Methods 25: 402-408.
17. MacEwen EG (1990). Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev. 9: 125-136.
18. Misdorp W, Else RW, Héllmén E and Lipscomb TP (1999). Histological Classification of Mammary Tumors of the Dog and the Cat. Armed Forces Institute of Pathology, Washington.
19. Monton M, Lopez-Farre A, Mosquera JR, Sanchez de ML, et al. (1997). Endogenous angiotensin II produced by endothelium regulates interleukin-1beta-stimulated nitric oxide generation in rat isolated vessels. Hypertension 30: 1191-1197.
20. Moulton JE (Editor) (1990). Tumors of the Mammary Gland. In: Tumors in Domestic Animals. 3rd edn. University of California Press, California, 518-550.
21. Perez Alenza MD, Pena L, del Castillo N and Nieto AI (2000). Factors influencing the incidence and prognosis of canine mammary tumours. J. Small Anim. Pract. 41: 287-291.
22. Queiroga F and Lopes C (2002). Tumores Mamários Caninos: Novas Perspectiva. In: Congresso de Ciências Veterinárias, Oeiras. Sociedade Portuguesa de Ciências Veterinárias, Lisboa, 183-190.
23. Schmidt A, Bengtsson A, Tylman M and Blomqvist L (2007). Pro-inflammatory cytokines in elective flap surgery. J. Surg. Res. 137: 117-121.
24. Schwaninger R, Rentsch CA, Wetterwald A, van der Horst G, et al. (2007). Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am. J. Pathol. 170: 160-175.
25. Simeone AM, Nieves-Alicea R, McMurtry VC, Colella S, et al. (2007). Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int. J. Oncol. 30: 785-792.
26. Slater D (Editor) (2007). Oncology in Reproductive System. In: Manual of Small Animal Surgery. 2nd edn. Manole, São Paulo, 2566-2592.
27. Snoussi K, Mahfoudh W, Bouaouina N, Ahmed SB, et al. (2006). Genetic variation in IL-8 associated with increased risk and poor prognosis of breast carcinoma. Hum. Immunol. 67: 13-21.
28. Sorenmo K (1998). An Update on Canine Mammary Gland Tumors. In: Proceedings of the 16th Annual ACVIM Veterinary Medical Forum, San Diego, 387-388.
29. Sorenmo KU, Kristiansen VM, Cofone MA, Shofer FS, et al. (2009). Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet. Comp. Oncol. 7: 162-172.
30. Thomas E and Berner G (2000). Prognostic and predictive implications of HER2 status for breast cancer patients. Eur. J. Oncol. Nurs. 4: 10-17.
31. van't Veer LJ, Paik S and Hayes DF (2005). Gene expression profiling of breast cancer: a new tumor marker. J. Clin. Oncol. 23: 1631-1635.
32. Vazquez-Martin A, Colomer R and Menendez JA (2007). Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur. J. Cancer 43: 1117-1124.
33. Wahl LM and Kleinman HK (1998). Tumor-associated macrophages as targets for cancer therapy. J. Natl. Cancer Inst. 90: 1583-1584.
34. Wang J, Huang M, Lee P, Komanduri K, et al. (1996). Interleukin-8 inhibits non-small cell lung cancer proliferation: a possible role for regulation of tumor growth by autocrine and paracrine pathways. J. Interferon Cytokine Res. 16: 53-60.
35. Yao C, Lin Y, Ye CS, Bi J, et al. (2007). Role of interleukin-8 in the progression of estrogen receptor-negative breast cancer. Chin. Med. J. 120: 1766-1772.
36. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, et al. (1987). Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc. Natl. Acad. Sci. U. S. A. 84: 9233-9237.
37. Zhou S, Wang GP, Liu C and Zhou M (2006). Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer 6: 231.
38. Zuccari DAPC, Santana AE and Rocha NS (2001). Fine needle aspiration cytologic and histologic correlation in canine mammary tumors. Braz. J. Vet. Res. Anim. Sci. 38: 38-41.
39. Zuccari DAPC, Pavam MV, Terzian ACB, Pereira RS, et al. (2008). Immunohistochemical evaluation of e-cadherin, Ki-67 and PCNA in canine mammary neoplasias: correlation of prognostic factors and clinical outcome. Pesq. Vet. Bras. 28: 207-215.